Moderna company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A rebound in healthcare equities in the week leading up to Aug. 21 traced back to trading momentum around clinical news tied to Moderna’s work and a Merck cancer study, according to a Yahoo Finance market recap.
THE APEX TIMES
THE APEX TIMES
The biotech said it plans a private placement of convertible senior notes and a “capped call” transaction meant to reduce potential dilution from any future conversion.
THE APEX TIMES
In a recent Mad Money segment, Cramer focused on Moderna’s mRNA platform as a caller recounted a sharp move in the stock and asked whether to sell or hold after a phase 3 cancer trial update.
THE APEX TIMES
A Yahoo Finance wrap-up of second-quarter results put Moderna’s performance in context with other healthcare therapeutics stocks, underscoring how investors weigh growth, pipeline progress, and near-term fundamentals.
THE APEX TIMES
The companies said their Phase 3 trial of intismeran plus Merck’s Keytruda met its stated goals in a study of 1,137 patients.
THE APEX TIMES
The biotechnology company said it is raising additional capital to support oncology work, shortly after regulators cleared updated COVID-19 vaccines for the next phase of use.
THE APEX TIMES
Shares of BioNTech SE fell sharply after news of an mRNA trial failure, reversing a recent momentum rally across companies developing mRNA-based therapies. The move is drawing fresh attention to how investors are differentiating outcomes across the group, with Moderna often acting as the benchmark given its larger late-stage pipeline.
THE APEX TIMES
The biotech company said the larger-than-original debt sale will fund general corporate needs, including flexibility for its oncology plans and repayment of existing debt, alongside hedging actions tied to the notes.
THE APEX TIMES
The melanoma headline from Moderna and Merck pushed Tempus AI higher, intensifying debate over whether Tempus’ $1.5 billion purchase of Personalis is beginning to look strategically right. The companies have not laid out how quickly the clinical readout would translate into near-term revenue.
